Mexico The lowest spender on healthcare as a percentage of GDP in mainland Latin America. A complex and fragmented reimbursement system. Clinical trial approval delays stretching across eight months. One could be forgiven for thinking that attempting to bring innovative medicines to Mexico is a thankless task. Yet, as several country…
Mexico Hernán Porcile, General Manager of Takeda Mexico, discusses the company’s innovative therapies, regulatory strategies, and the integration of ” “Takeda-ism” within the Mexican cultural context. He emphasizes Takeda’s commitment to sustainability, diversity, and collaboration with local healthcare ecosystems. Respecting our legacy as a Japanese company while adapting to the…
Japan A roundup of the most important stories coming out of Japan’s pharma industry, including the sharp increase in deaths linked to Kobayashi supplements; the partnership between Moderna and Mitsubishi Tanabe to jointly promote Moderna’s mRNA respiratory vaccine portfolio; the country’s move to to support domestic antibiotics production; Takeda’s licenscing agreement…
Japan Some of the biggest stories coming out of Japanese pharma, including Takeda’s USD 2.2 billion Alzheimer’s deal with AC Immune and its plans to restructure; the continuing probe into deaths linked to a Kobayashi Pharmaceutical supplement; Kyowa Kirin’s acquisition of Orchard Therapeutics, and Shionogi’s buy up of Maze Therapeutics’ Pompe…
China Amid geopolitical tensions and a drop in foreign investments, China continues to encourage international companies to increase their Chinese footprint. At this week’s China Development Forum (CDF), CEOs from Pfizer, AstraZeneca, Bayer, Bristol Myers Squibb, GSK, Novartis, and Takeda made it clear that Big Pharma’s interest in the country has…
UAE Over the past few decades, the UAE has worked hard to attract top global talent to fill the gaps that its small local population was unable to. While the high salaries on offer were previously the main attractor to the country, with workers often staying for a couple of years…
Belgium Encircled by heavyweight life sciences powerhouses of the likes of Germany, France and Switzerland, plucky Belgium nonetheless continues to astonish and project considerable influence when it comes to its abilities to develop, manufacture and sell medicines. Despite representing only a mid-size marketplace from an in-country commercial perspective, the comparatively…
UAE Rodrigo Rodriguez, as area head for UMEA at Takeda, leads a vast and varied region that includes Ukraine, the Middle East and Africa and is characterised by what he calls “geographical and economic volatility,” with an extreme example being the conflict in Ukraine. He discusses the challenges presented by the…
Takeda Japanese-headquartered Takeda has been undergoing a transformation in recent years, becoming the global leader in rare diseases with the acquisition of Shire in 2018 and divesting ‘non-core’ assets in OTC and consumer goods. Here, four country and regional managers that PharmaBoardroom has spoken to in the past 12 months discuss…
Greece After 15 years of economic struggles coupled with political swings to the left and right, Greece seems to be on its surest footing in decades. Indeed, the Economist observed that the May 2023 election victory of incumbent Greek Prime Minister Kyriakos Mitsotakis (and the heavy defeat handed to his left…
Greece Greece is a middling performer in terms of clinical trial numbers on the European stage, nestled next to Finland and Romania on total trial numbers between 2002 and 2020 but ahead of Germany and Italy on trials per capita. However, the pharmaceutical industry does see opportunities for establishing greater trial…
LatAm A vibrant and diverse continent, home to over 650 million people and the highest life expectancy among developing regions, Latin America is now emerging as a globally relevant life sciences investment destination. LatAm has a robust heritage of scientific achievement – Bernardo Houssay (1947) and César Milstein (1984) of Argentina…
See our Cookie Privacy Policy Here